Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The distribution of 14C-APD and 99mTc-APD (APD = 3-amino-1-hydroxypropane-1,1-diphosphonic acid) in untreated rats and in rats bearing intratibially transplanted osteosarcomas was investigated autoradiographically and scintigraphically. Also investigated was the effect of high doses of APD on survival time and tumor growth of osteosarcoma-bearing rats. Intravenous administration of APD resulted in high rates of APD accumulation in bones, tumor tissue and pulmonary metastases as well as in dose-related accumulation in the liver. No significant increase in the median survival time of tumor-bearing animals was achieved at the two dosage schemes tested, i.e. 2 X 23.5 mg/kg and 10 X 11.75 mg/kg APD. The growth of primary tumors was slightly increased by administration of APD. The chemosensitivity of the transplantable osteosarcoma model was demonstrated by comparison with dacarbazine-treated control animals.
 ...
PMID:Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma. 386 53

The authors treated 18 patients with Paget's disease of bone (12 men and 6 women, age 65 +/- 5 years) with pamidronate (bisphosphonate of the second generation). Three patients from this group were treated previously without success with calcitonin or bisphosphonate of the first generation (etidronate) 50% of the patients suffered from the polyostotic form of the disease. In one patient a rare combination of primary hyperparathyroidism with Paget's bone disease was found and in another patient later an osteosarcoma developed in the affected bone. To all patients sodium pamidronate was administered (Aredia, Ciba-Geigy) 30 mg per day by i.v. infusion for 2 hours during three days. Four patients developed fever, two patients phlebitis at the site of injection. These side-effects are described by the manufacturer. Two patients developed transient regional alopecia, not described so far. Subjective pain relief of the affected skeleton occurred in one patient after one month of treatment, after three months in 78%. Laboratory manifestations of activity of the disease (serum activity of alkaline phosphatase, tartrate resistant acid phosphatase and hydroxyprolinuria) declined gradually from the 1st to the 6th month after onset of treatment. There was a less marked decline of the osteocalcin serum concentration. The concentration of calcium, phosphorus and vitamin D metabolites did not change markedly. Twelve months after treatment 14.7% of the patients were inactive according to laboratory tests, 73% however experienced another rise of parameters of osteoresorption and osteoformation. Pamidronate treatment in patients with Paget's disease of bone is effective and safe.
 ...
PMID:[Paget's disease of bone and treatment with pamidronate]. 837 65